TScan Therapeutics announced the completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial, utilizing a manufacturing process designed for commercial-scale production. Simultaneously, the company received FDA clearance for investigational new drug applications targeting two heme-derived candidates, TSC-102-A01 and TSC-102-A03, which are engineered to address CD45 expression in patients with HLA types A01:01 and A03:01 respectively.
The advancement represents a significant milestone in TScan's allogeneic cell therapy development strategy. The completion of Cohort C enrollment demonstrates progress in establishing the safety and efficacy profile of the ALLOHA™ platform using manufacturing processes that align with potential commercial requirements. The dual IND clearances expand the company's pipeline by enabling early-stage clinical evaluation of the TSC-102 candidates.
Looking ahead, TScan intends to present safety and chimerism data from the ALLOHA™ trial in the second quarter of 2026. The company also plans to initiate a pivotal trial for TSC-101 and launch Phase 1 studies for both TSC-102 candidates during the second half of 2026. These upcoming milestones will be critical in evaluating the therapeutic potential of TScan's engineered cell therapy approach across multiple candidate programs.